NEW YORK, June 7, 2017 /PRNewswire/ --
On Tuesday, June 06, 2017, US
markets saw broad based losses with six out of nine sectors
finishing the trading sessions in red. Major US indices were also
bearish at the close of yesterday's session. The NASDAQ Composite
ended the day at 6,275.06, down 0.33%; the Dow Jones Industrial
Average edged 0.23% lower, to finish at 21,136.23; and the S&P
500 closed at 2,429.33, down 0.28%. This Wednesday morning,
DailyStockTracker.com looks at the performance of these four Drugs
- Generic stocks: Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX),
Lannett Co. Inc. (NYSE: LCI), Evoke Pharma Inc. (NASDAQ: EVOK), and
Galectin Therapeutics Inc. (NASDAQ: GALT). This morning's free research reports on
the aforesaid equities can be accessed upon registration on
DailyStockTracker.com at:
http://dailystocktracker.com/register/
Catalyst Pharma
Coral Gables, Florida-based
Catalyst Pharmaceuticals Inc.'s stock finished Tuesday's session
2.94% lower at $2.31 with a total
trading volume of 382,535 shares. The Company's shares have surged
36.69% in the past month, 106.25% over the previous three months,
and 120.00% on an YTD basis. The stock is trading above its 50-day
and 200-day moving averages by 21.67% and 73.14%, respectively.
Furthermore, shares of Catalyst Pharma, which focuses on the
development and commercialization of therapies for people with rare
debilitating diseases, have a Relative Strength Index (RSI) of
65.77. Visit us today and download your complete report on CPRX for
free at:
http://dailystocktracker.com/registration/?symbol=CPRX
Lannett
Shares in Philadelphia,
Pennsylvania-based Lannett Co. Inc. ended at $19.65, down 0.25% from the last trading session.
The stock recorded a trading volume of 428,488 shares. The
Company's shares are trading 13.26% below their 50-day moving
average. Moreover, shares of Lannett, which develops, manufactures,
packages, markets, and distributes generic versions of brand
pharmaceutical products in the US, have an RSI of 36.78. The
complimentary research report on LCI can be accessed at:
http://dailystocktracker.com/registration/?symbol=LCI
Evoke Pharma
Solana Beach, California
headquartered Evoke Pharma Inc.'s stock ended yesterday's session
0.78% higher at $2.57 with a total
trading volume of 67,077 shares. The Company's shares have advanced
27.23% on an YTD basis. The stock is trading 9.10% above its
200-day moving average. Additionally, shares of Evoke Pharma, which
focuses on the development of drugs for the treatment of
gastroenterological disorders and diseases, have an RSI of 43.12.
Register for free on DailyStockTracker.com and download the
research report on EVOK at:
http://dailystocktracker.com/registration/?symbol=EVOK
Galectin Therapeutics
On Tuesday, shares in Norcross,
Georgia-based Galectin Therapeutics Inc. recorded a trading
volume of 312,987 shares. The stock finished 1.74% higher at
$2.34. The Company's shares have
advanced 37.65% in the previous three months and 138.82% since the
start of this year. The stock is trading above its 200-day moving
average by 42.50%. Furthermore, shares of Galectin Therapeutics,
which engages in the research and development of therapies for
fibrotic disease and cancer, have an RSI of 44.13. Get free access
to your research report on GALT
at:
http://dailystocktracker.com/registration/?symbol=GALT
--
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and
non-sponsored reports, articles, stock market blogs, and popular
investment newsletters covering equities listed on NYSE and NASDAQ
and micro-cap stocks. DST has two distinct and independent
departments. One department produces non-sponsored analyst
certified content generally in the form of press releases, articles
and reports covering equities listed on NYSE and NASDAQ and the
other produces sponsored content (in most cases not reviewed by a
registered analyst), which typically consists of compensated
investment newsletters, articles and reports covering listed stocks
and micro-caps. Such sponsored content is outside the scope of
procedures detailed below.
DST has not been compensated; directly or indirectly; for
producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by
a writer (the "Author") and is fact checked and reviewed by a third
party research service company (the "Reviewer") represented by a
credentialed financial analyst [for further information on analyst
credentials, please email contact@dailystocktracker.com.
Rohit Tuli, a CFA® charterholder
(the "Sponsor"), provides necessary guidance in preparing the
document templates. The Reviewer has reviewed and revised the
content, as necessary, based on publicly available information
which is believed to be reliable. Content is researched, written
and reviewed on a reasonable-effort basis. The Reviewer has not
performed any independent investigations or forensic audits to
validate the information herein. The Reviewer has only
independently reviewed the information provided by the Author
according to the procedures outlined by DST. DST is not entitled to
veto or interfere in the application of such procedures by the
third-party research service company to the articles, documents or
reports, as the case may be. Unless otherwise noted, any content
outside of this document has no association with the Author or the
Reviewer in any way.
NO WARRANTY
DST, the Author, and the Reviewer are not responsible for any
error which may be occasioned at the time of printing of this
document or any error, mistake or shortcoming. No liability is
accepted whatsoever for any direct, indirect or consequential loss
arising from the use of this document. DST, the Author, and the
Reviewer expressly disclaim any fiduciary responsibility or
liability for any consequences, financial or otherwise arising from
any reliance placed on the information in this document.
Additionally, DST, the Author, and the Reviewer do not (1)
guarantee the accuracy, timeliness, completeness or correct
sequencing of the information, or (2) warrant any results from use
of the information. The included information is subject to change
without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or
a solicitation of an offer to buy or sell the securities mentioned
or discussed, and is to be used for informational purposes only.
Please read all associated disclosures and disclaimers in full
before investing. Neither DST nor any party affiliated with us is a
registered investment adviser or broker-dealer with any agency or
in any jurisdiction whatsoever. To download our report(s), read our
disclosures, or for more information, visit
http://dailystocktracker.com/disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly.
If you're a company
we are covering and wish to no longer feature on our coverage list
contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday
at:
Email: contact@dailystocktracker.com
Phone number: (207)331-3313
Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE Chelmsford Park SA